TVTX logo

TRAVERE THERAPEUTICS INC

TVTXNASDAQ
🏆 #1231 by market capEarnings Oct 22US Equity
$59.98▼ $1.58 (−2.63%)
After hours · at close
🔔
Track TVTX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.6%
7d▼ 0.5%
14d▼ 4.1%
30d▼ 8.7%
ytd▲ 56.9%
1y▲ 149.5%
🏦Market Cap
$5.58B
Small Cap
📈Revenue Growth (YoY)
+77.1%
High Growth
📊Gross Margin
98.6%
High
💵FCF Margin
13.3%
Healthy
⚖️P/S Ratio
9.5x
Elevated
Otter Score
40
Weak

Trading Snapshot

Day Range
$59.11 – $60.28
52-Week Range
$22.06 – $68.73
Volume
$3.10B
Avg Volume
$3.11B
Shares Outstanding
93.0M
Next Earnings
Dec 13, 2026

Fundamentals Snapshot

Annual Revenue
$491M
Last Q Revenue
$170M
P/E Ratio
—
P/S Ratio
9.5x
EPS (TTM)
$-0.50
Dividend Yield
—
Dilution (1yr)
+8.7%

Why Investors Own TVTX

  • ✓High-growth profile — revenue up -5.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 26% gross margin and 14% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TVTX logo

TRAVERE THERAPEUTICS INC

TVTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$491M▲ +110.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.9%▲ +1.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$63M▼ −80.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$20M▼ −94.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
90.3M▲ +8.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$247M▲ +$96M YoY
StockOtter · stockotter.space

About TRAVERE THERAPEUTICS INC

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
40/100

Analyst Price Target

ⓘ
Average Target
$67.49
▲ +12.5% Upside
High Target$77.01
Low Target$60.63
Based on 41 analysts

Latest News & Updates

🚀
Reuters·2h ago

TRAVERE THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift TVTX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

TRAVERE THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.